GB0610746D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB0610746D0
GB0610746D0 GBGB0610746.0A GB0610746A GB0610746D0 GB 0610746 D0 GB0610746 D0 GB 0610746D0 GB 0610746 A GB0610746 A GB 0610746A GB 0610746 D0 GB0610746 D0 GB 0610746D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0610746.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Priority to GBGB0610746.0A priority Critical patent/GB0610746D0/en
Publication of GB0610746D0 publication Critical patent/GB0610746D0/en
Priority to EP07733734A priority patent/EP2029124A1/en
Priority to US12/303,028 priority patent/US20090258816A1/en
Priority to JP2009512684A priority patent/JP2009538898A/ja
Priority to PCT/GB2007/050313 priority patent/WO2007138362A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0610746.0A 2006-06-01 2006-06-01 Method of treatment Ceased GB0610746D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0610746.0A GB0610746D0 (en) 2006-06-01 2006-06-01 Method of treatment
EP07733734A EP2029124A1 (en) 2006-06-01 2007-06-01 Use of gpcr agonists to delay progression of diabetes
US12/303,028 US20090258816A1 (en) 2006-06-01 2007-06-01 Use of gpcr agonists to delay progression of diabetes
JP2009512684A JP2009538898A (ja) 2006-06-01 2007-06-01 糖尿病の進行を遅らせるためのｇｐｃｒアゴニストの使用
PCT/GB2007/050313 WO2007138362A1 (en) 2006-06-01 2007-06-01 Use of gpcr agonists to delay progression of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610746.0A GB0610746D0 (en) 2006-06-01 2006-06-01 Method of treatment

Publications (1)

Publication Number Publication Date
GB0610746D0 true GB0610746D0 (en) 2006-07-12

Family

ID=36694688

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0610746.0A Ceased GB0610746D0 (en) 2006-06-01 2006-06-01 Method of treatment

Country Status (5)

Country Link
US (1) US20090258816A1 (enExample)
EP (1) EP2029124A1 (enExample)
JP (1) JP2009538898A (enExample)
GB (1) GB0610746D0 (enExample)
WO (1) WO2007138362A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20100130476A1 (en) * 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
JP5378825B2 (ja) * 2009-02-17 2013-12-25 出光興産株式会社 Ｇｐｒ１１９アゴニスト
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8293729B2 (en) * 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) * 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
EP2999783A2 (en) * 2013-05-23 2016-03-30 University of Bremen Novel treatment of metabolic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US8207147B2 (en) * 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Also Published As

Publication number Publication date
US20090258816A1 (en) 2009-10-15
JP2009538898A (ja) 2009-11-12
EP2029124A1 (en) 2009-03-04
WO2007138362A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
EP2032131A4 (en) Methods of Treatment
HRP20190408T1 (hr) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
IL193460A0 (en) Compounds and methods for treatment of stroke
IL192555A0 (en) Method of treating multiple sclerosis
ZA200901364B (en) Method of treatment of photodermatoses
IL193183A0 (en) Method of treatment for muscular dystrophy
IL212348A0 (en) Treatment method
IL208354A0 (en) Methods of treatment
ZA200806349B (en) Method for treatment of neuropathic pain
GB0605360D0 (en) Method of manufacture
GB0718684D0 (en) Treatment method
GB0607293D0 (en) Plant treatment method
GB0608190D0 (en) Method of purification
EP2088862A4 (en) METHOD OF TREATING CANCER
ZA200900638B (en) Method of diagnosis
EP2164494A4 (en) Methods of Treatment
IL202002A0 (en) Method of treating diabetes
EP2194793A4 (en) PROCESS FOR TREATING FRESH FRUITS AND VEGETABLES
GB0723100D0 (en) Treatment of HFnEF
ZA200900639B (en) Method of diagnosis
EP2094385A4 (en) METHOD OF WASTE WATER TREATMENT
PL2009121T3 (pl) Sposób przetwarzania odpadów
EP2203432A4 (en) PROCESSING METHOD
GB0607153D0 (en) Therapeutic Method
GB0618060D0 (en) Treatment of polyamides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)